Q-omics provides the consensus-scored MIR34B profile across patient tissues and cancer cell-line models. MIR34B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR34B is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR34B RNA expression shows 8,088 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUAD, and THYM as cancer lineages where MIR34B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR34B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR34B survival associations across molecular data types. MIR34B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR34B RNA expression–survival associations across cancer types. High MIR34B expression shows unfavorable associations in HNSC, ACC, STAD and KIRC, but favorable associations in UCEC and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR34B RNA expression.
This table summarizes MIR34B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR34B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR34B shows lower tumor expression in LUAD, LUSC and THCA. The LUAD box plot shows higher MIR34B RNA expression in normal versus tumor tissue (log2 FC = −1.435, t-test p < 0.001).
This table shows molecular features associated with MIR34B in patient tissues and cancer cell lines. In patient samples, MIR34B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
